share_log
Reuters ·  May 8 08:00
Acumen Pharmaceuticals Announces First Patient Dosed in Altitude-Ad, a Phase 2 Clinical Trial of Sabirnetug (Acu193) in Early Alzheimer’s Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment